You are on page 1of 12

MORBILI

Prof H Widagdo, Dr, SpA, MBA


Bagian Ilmu Kesehatan Anak
Fakultas Kedokteran Univ Trisakti
DEFINITION
 MORBILI, RUBEOLA, MEASLES, CAMPAK

 … IS AN ACUTE VIRAL INFECTION


CHARACTERIZED BY MACULO-PAPULAR
RASH ERUPTING OVER THE NECK, FACE,
BODY, ARMS AND LEGS AND
ACCOMPANIED BY HIGH FEVER.
ETIOLOGY
 RNA VIRUS, GENUS MORBILLIVIRUS,
FAMILY PARAMYXOVIRIDAE
 ONE SEROTYPE
 FOUND IN NASOPHARYNX
SECRETIONS, BLOOD, AND URINE
 ACTIVE IN ROOM TEMP FOR 34 HR
EPIDEMIOLOGY
 WORLD WIDE ENDEMIC
 PEAK INCIDENCE 5 -10 Y OLD
 INCIDENCE  BY MASSIVE VACC
 90% IMM COVERAGE MORBILLI-
FREE AREA
 TRANSMISSION: DROPLET SPRAY
DURING PRODROMAL PHASE
 TRANSPLACENTAL IMMUNITY
PATHOGENESIS
 GENERAL INFLAMMATION, HYPERPLASIA
OF LYMPHOID TISSUE, DEMYELINATION
AND DEGENERATION OF THE BRAIN
 SKIN: MACULO-PAPULAR RASH
 RESP: NASOPHARYNGITIS, PNEUMONIA
 BUCCAL MUCOSE: KOPLIK SPOTS
 CONJUNCTIVA: INFLAMMATION
 CNS: ENCEPHALOMYELITIS, SSPE
CLINICAL MANIFESTATIONS

 INCUBATION PERIOD OF 7-10 DAYS


 PRODROMAL PHASE: MILD FEVER,
COUGH, CORYZA, CONJUNCTIVITIS, AND
ENANTHEEM -KOPLIK’S SPOT.
 SKIN RASH: MACULA, MACULOPAPULA,
HYPERPIGMENTED DESQUAMATION.
CERVICAL LNN >, SPLEEN >
 RECONVALESCENCE STAGE.
DIAGNOSIS
 BASED MAINLY ON CLINICAL PICTURE
 LAB EXAM IS RARELY NEEDED
 LEUKOPENIA W/ LYMPHOCYTOSIS
 NASPHAR SMEAR: MNC GIANT CELL
 SEROLOGY 4 X  OF AB
 MORBILLI VIRUS ISOLATION
 CSF IN CBR COMPL: MILD  OF PROTEIN
AND LYMPHOCYTES
DIFFERENTIAL DIAGNOSIS
 RUBELLA, ROSEOLA INFANTUM
 ECHO,COXSACKIE, ADENO VIRAL
INF
 MONONUCL INF, TOXOPLASM,
 MENINGOCOCCEMIA, SCARLET
FEVER, RICKETTSIAL
 KAWASAKI, SERUM SICKNESS,
DRUG RASH
COMPLICATIONS
 OTITIS,PNEUMONIA, ENCEPHALITIS
 NOMA, GANGRENE
 TBC EXACERBATION
 MYOCARDITIS
 GUILLAIN-BARRE SYNDROME,
HEMIPHLEGIC, CBR
THROMBOPHLEBITIS,
RETROBULBAR NEURITIS
TREATMENT
 NO SPECIFIC ANTIVIRAL DRUG
 SUPPORTIVE AND SYMPTOMATIC
 ANTIBIOTICS FOR 2NDARY INF
 90% CASES WITH HYPORETINEMIA
VIT SUPPL OF 100,000 U FOR < 1Y
OLD, OR 200,000 U FOR > I Y OLD
WILL  MBY AND MTY
PROGNOSIS
 MTY RATES 1-2 PER 1,000 CASES
PREVENTIVE MEASURES

 ACTIVE:MEASLES VACCINE
 PASSIVE: IMMUNE GLOBULIN FOR
POST EXPOSURE CHILD